The effect of diazepam on presynaptic inhibition in patients with complete and incomplete spinal cord lesions

Role of oral medications in spasticity management

Oral medications are frequently used to manage spasticity. Some clinicians may believe that oral medications are a more conservative or "first-line" strategy to treat this condition. However, their use may lead to significant adverse events. Additionally, efficacy has not been well-established, in particular the ability of these medications to enhance functional outcome. The decision regarding the use of oral medications is further complicated by the fact that a number of different agents have been used for many different diagnoses. The relative dearth of well-controlled studies makes the choice of medications for a given clinical condition even more difficult. This article reviews the mechanisms of action of some of the medications that are more commonly used to treat spasticity and identifies some studies that may suggest efficacy, or lack thereof, for certain diagnoses. Because questions remain regarding the benefit of oral medications, potential side effects also are emphasized to help the reader consider both potential risks and benefits. The article is intended as a broad overview, rather than comprehensive review of the literature.

The spinal pathophysiology of spasticity--from a basic science point of view

Spasticity is a term, which was introduced to describe the velocity-sensitive increased resistance of a limb to manipulation in subjects with lesions of descending motor pathways. This distinguishes spasticity from the changes in passive muscle properties, which are often seen in these patients, but are not velocity-sensitive. Increased excitability of the stretch reflex is thus a central component of the definition of spasticity. This review describes changes in cellular properties and transmission in a number of spinal reflex pathways, which may explain the increased stretch reflex excitability. The review focuses mainly on results derived from the use of non-invasive electrophysiological techniques, which have been developed during the past 20-30 years to investigate spinal neuronal networks in human subjects, but work from animal models is also considered. The reflex hyperexcitability develops over several months following the primary lesion and involves adaptation in the spinal neuronal circuitries caudal to the lesion. In animal models, changes in cellular properties (such as 'plateau potentials') have been reported, but the relevance of these changes to human spasticity has not been clarified. In humans, numerous studies have suggested that reduction of spinal inhibitory mechanisms (in particular that of disynaptic reciprocal inhibition) is involved. The inter-subject variability of these mechanisms and the lack of objective quantitative measures of spasticity have impeded disclosure of a clear causal relationship between the alterations in the inhibitory mechanisms and the stretch reflex hyperexcitability. Techniques which make such a quantitative measure possible as well as longitudinal studies where development of reflex excitability and changes in the inhibitory mechanisms are followed over time are in great demand.

Effect of spinal cord injury severity on alterations of the H-reflex

The monosynaptic motoneuron response to stimulation of Ia afferents is known to be altered by spinal cord injury (SCI). Although the Hoffman (H)-reflex is a tool that is often used to measure this reflex in patients, there has not been a systematic study investigating the effect of SCI severity and time on the H-reflex. We used a clinically relevant model of spinal cord contusion (Mild and Moderate) as well as complete surgical transection to measure the H-reflex at 1, 4 and 8 weeks after injury. The H-reflex was recorded from rat hindpaw plantar muscles in order to measure the baseline reflex amplitude and its response to increased stimulus frequency, i.e. rate depression. We correlated the reflex amplitude at each frequency to spared white matter at the injury epicenter, hindlimb function and serotonin immunoreactivity associated with retrogradely labeled plantar muscle motoneurons. The three injury groups displayed different behavioral deficits and amount of spared white matter at all three times tested. H-reflex rate depression was abnormal in all three injury groups at all three time points. At 8 weeks, transected animals displayed more H-reflex rate depression than those with a mild contusion. Baseline H-reflex amplitude was increased in both contusion groups at 4 weeks and showed a positive linear correlation with serotonin immunoreactivity. This baseline amplitude was not increased after transection. Furthermore, in the contusion group, there was a U-shaped relationship between behavioral scores and H-reflex rate depression, suggesting that an intermediate sensitivity of the motoneuronal pool to afferent input is associated with better recovery of hindlimb function.

Reflex changes induced by clonidine in spinal cord injured patients

In a single blind study of 6 spinal cord injured (SCI) men, the effects of clonidine, a selective alpha-2 adrenergic agonist, on spasticity were compared to diazepam and placebo. Since a potential side-effect of clonidine is postural hypotension, a combination of clonidine and desipramine was also tested. Vibration of the leg will inhibit the H reflex in a normal subject; whereas, this inhibition is markedly reduced in SCI patients with spasticity. A vibratory inhibition index (VII) was derived for each treatment. The pre-treatment VII was 92.08 +/- 3.15%; for SCI subjects, compared to 46.5 +/- 7.7% for 6 normal subjects. Clonidine significantly reduced the mean index of SCI patients to 59.42 +/- 3.91% (p less than 0.001). The VII for placebo, diazepam and the clonidine-desipramine combination were not statistically different than the pre-treatment values in SCI patients. In conclusion, clonidine has an anti-spasticity effect in SCI patients, both subjectively, and objectively, in terms of vibratory inhibition of the H reflex.

Further studies on quantification of drug-induced tremor in mice: effects of antitremorgenic agents on tremor frequency

The effects of diazepam, dantrolene and atropine on drug-induced tremors were investigated in mice from the point of view of the tremor frequency. The study involved a power spectral analysis of the random current induced by movement of a magnet (attached to the mouse) on a wire coil. To induce tremor, tremorine and harmaline were subcutaneously injected. The power spectral density function defined the frequency composition of the tremor and its severity was determined quantitatively in terms of the mean square value of the data in any frequency range of concern. Diazepam markedly depressed the power spectral density of the tremorine- and harmaline-induced tremor and reduced the tremor frequency. With higher doses of diazepam, the peak frequency of the tremorine-induced tremor shifted to the lower frequency side as if the tremor components were taken into the component of the spontaneous motor activity. Dantrolene and atropine suppressed the power spectral density without affecting tremor frequency. The relationship between the change of tremor frequency and the site of action of antitremorgenic agents are discussed.

Antispasticity drugs: mechanisms of action

Several different drugs are now used, or are potentially useful, to treat patients with spasticity. Although these compounds vary in their actions on spinal neurons and reflex arcs, it is possible to formulate reasonable hypotheses regarding their modes of action. The benzodiazepines bind to specific benzodiazepine receptors linked to classic gamma-aminobutyric acid (GABA) receptors located on the terminals of primary afferent fibers. This binding results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Baclofen activates GABAB receptors putatively located on the same terminals. Activation of these receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters. Progabide and its metabolites act on both classic and GABAB receptors. Glycine works on specific inhibitory receptors located on spinal interneurons and motoneurons. The phenothiazines act on the brainstem to alter the function of fusimotor fibers. Phenytoin and carbamazepine reduce the afferent output of muscle spindles. Dantrolene diminishes the activation of the contractile process in muscle fibers by reducing the release of calcium ions from the sarcoplasmic reticulum. This review summarizes the data supporting these concepts.

Diazepam, a highly effective twitch potentiator in isolated muscle fibres of the frog

The contractile effects of diazepam (10-200 microM) were studied on twitch and tetanus responses of isolated fibres of the semitendinosus muscle of Rana temporaria (3.5-5.0 degrees C). Diazepam (100-200 microM) enhanced the twitch amplitude to 95-100% of maximum tetanic force and increased the rate of rise of force, the time to peak twitch force and the total duration of the relaxation phase. The maximum tetanic output was unaffected by diazepam but the drug increased the rate of rise of the tetanic force and delayed the onset of force decay after the last stimulus. However, the kinetics of relaxation was unaffected by the drug. Diazepam had no effect on either threshold, submaximum or maximum contracture responses to caffeine and to increased potassium concentration. Diazepam in concentrations producing full twitch potentiation caused only a moderate (ca 30%) increase in action potential duration. The results are in line with the idea that 1: diazepam enhances the twitch response by increasing the rate of release of activator calcium without affecting the rate of calcium resequestration and 2: diazepam acts by modulating a mechanism in the excitation-contraction coupling that responds specifically to membrane excitation.

Is chlordiazepoxide the rational choice among benzodiazepines?

Diazepam is frequently the subject of review by various agencies and institutions charged with determining whether or not to substitute another, more economical drug--in most instances, chlordiazepoxide. A review of the comparative literature has shown that, on clinical and pharmacokinetic grounds, chlordiazepoxide is not the drug of choice for all clinical indications recommended for the benzodiazepines as a class, particularly for use as an antianxiety agent. There is evidence that the antianxiety effect of chlordiazepoxide is related to the appearance of its two active metabolites, which may explain the observed delay in its onset of action. When chlordiazepoxide's reduced clearance in the elderly and in patients with liver disease is considered along with its limited range of indications, substitution of diazepam with chlordiazepoxide is clearly not reasonable. Diazepam and lorazepam are preferred choices in acute anxiety because they are themselves active anxiolytics. Oxazepam is recommended in alcoholic cirrhotics because its plasma clearance does not seem to be significantly affected by liver disease. Diazepam is recommended for chronic anxiety because of the rapid onset of action of diazepam itself and the smooth transition to the nondrug state via its longer-acting active metabolite.

The effect of diazepam on tension and electrolyte distribution in frog muscle

The effect of diazepam on sartorius muscles of the frog was evaluated. Resting tension in sartorius muscle was not affected by diazepam (5 x 10(-5)M) but twitch tension was increased and tetanus tension decreased. The kinetics of 45Ca efflux were altered by diazepam. The calcium content of the intermediate pool was increased by diazepam (5 x 10(-6)M). When the diazepam concentration was increased (5 x 10(-5)M), the time constant of the slow pool decreased and the 45Ca content of the intermediate pool increased further. It is suggested that diazepam interferes with the calcium sequestering system of the sarcoplasmic reticulum (slow pool) and causes an increase of the calcium content of the myofibrillar space (intermediate pool).

Correlation of changes in the GABA-ergic system with the development of spasticity in paraplegic cats

Following spinal cord transection there occurred decreases in Km and Vmax of glutamate decarboxylase (GAD) both above and below the lesion, and an initial decrease in the concentration of GABA. Concomitantly, there was a gradual decrease in presynaptic inhibition. Eight to 12 weeks after spinal cord transection, Km and Vmax for GAD returned to control values, but the GABA content of the spinal cord below the lesion increased significantly and presynaptic inhibition became maximally depressed. These results suggested that during the chronic phase of spinal cord injury there is a decrease in release of GABA, the interneuronal inhibitory neurotransmitter which mediates presynaptic inhibition. Diazepam, a GABA enhancer, increased presynaptic inhibition in acute and chronic spinal cats, this being accompanied by a reduction in somatic muscular spasticity. The degree of this enhancement by diazepam, however, is attenuated with gradual loss of presynaptic inhibition. In the acute cat, a conditioning volley applied to cutaneous afferents blocked the inhibition of the monosynaptic response to extensor motoneurones. In contrast, in chronic spinal cats (eight to 12 weeks), the duration of complete blockade was markedly reduced and was followed by a prolonged period which cutaneous nerve stimulation potentiated the monosynaptic discharge. Similar to GABA, there also occurred an increase of substance P below the level of the lesion. Other neurotransmitters (e.g., norepinephrine, serotonin) accumulated above and disappeared below the transection level. Although somatic msucular spasticity appears to be, to some extent, due to GABA dysfunction in the spinal cord, alterations in "normal" functioning of other neurotransmitters and the loss of supraspinal control also contribute to this state.

Ethanol and spinal presynaptic inhibition in man

Ethanol, 0.65 gm per kilogram of body weight, was administered orally to 6 normal subjects. The mean blood ethanol levels ranged from 0.74 to 0.99 gm per liter over a subsequent 40-minute testing period. The proportion of the soleus motoneuron pool activated by the Achilles tendon reflex was reduced. Vibratory inhibition of the monosynaptic reflex was used as an estimate of spinal presynaptic inhibition. It was unaffected by ethanol.